Mutational Landscape in Hepatocellular Carcinoma

NCT03071458 | Completed

• 1 other identifier: C 16-71
• Study Type: observational
• Target: 808
• Locations: 1 country
• Sites: 1

Brief Summary

The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of circulating tumor DNA.

Conditions

HepatoCellular Carcinoma; Cirrhosis

Outcome Measures

Primary Outcomes (1)

• Genetic and transcriptomic landscape

  Identification of the main genetic driver and transcriptomic subgroups among a large panel of HCC

  Up to 3 years

Secondary Outcomes (3)

• Translation in immunohistochemical markers

  Up to 3 years

• Detection and sequencing of circulating tumor DNA as a liquid biopsy in HCC

  Up to 3 years

• Validation of the molecular classification by integrative analysis

  Up to 3 years

Study Arms (1)

Patients with HCC

The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with hepatocellular carcinoma

You may qualify if:

• Written consent of the patient according to the French Law: the French Liver Biobanks network - AFAQ NF S96-900 and Hepatobio bank
• Histologically proven hepatocellular carcinoma
• Available frozen samples
• HCC assessible to a curative treatment (Treated by resection, liver transplantation, radio frequency ablation) or advanced HCC with available biopsy

You may not qualify if:

• Less than 18 years old
• Pregnancy at the date of the sample
• Parafinn embedded tissue only available

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead

Study Sites (1)

INSERM

Paris, 75010, France

Location

Related Publications (1)

• Blaise L, Ziol M, Campani C, Ganne-Carrie N, Nahon P, Nkontchou G, Zucman-Rossi J, Del Pozo L, Barget N, Boros C, Desjonqueres E, Demory A, Grando V, Pescatori L, Seror O, Sutter O, Nault JC. Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma. JHEP Rep. 2025 Apr 22;7(9):101430. doi: 10.1016/j.jhepr.2025.101430. eCollection 2025 Sep.

  PMID: 40823168 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

224 tumor (HCC) and 224 non tumor samples from liver transplantation 129 tumor (HCC) and 129 non tumor samples from radio frequency ablation 342 tumor (HCC) and 342 non tumor samples from liver resection 40 tumor (HCC) and 35 non tumor samples from biopsies of advanced HCC 277 plasmas of 78 patients for circulating tumor DNA analysis

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Fibrosis

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• jessica zucman-rossi, Md,Phd

  Institut National de la Santé Et de la Recherche Médicale, France

  PRINCIPAL INVESTIGATOR

• jean-charles Nault

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2017
• First Posted: March 7, 2017
• Study Start: January 1, 2008
• Primary Completion: May 1, 2015
• Study Completion: May 1, 2015
• Last Updated: December 10, 2025

Record last verified: 2017-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)